Loomis, Sayles & Company
IRON icon

Loomis, Sayles & Company’s Disc Medicine IRON Stock Holding History

Loomis, Sayles & Company’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3M Buy
317,222
+34,813
+12% +$2.42M 0.03% 237
2025
Q4 		$22.4M Buy
+282,409
New +$23.9M 0.03% 221

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Loomis, Sayles & Company's IRON Position: Q1 2026 in Review

Loomis, Sayles & Company increased its Disc Medicine (IRON) stake by 12% in Q1 2026, buying an estimated $2.42M and bringing the position to 317,222 shares worth $20.3M. The position accounts for 0.03% of the portfolio, ranked #237.

Loomis, Sayles & Company first reported a position in IRON in Q4 2025 and has held it in 2 quarters since. The position peaked at $22.4M in Q4 2025. 203 funds tracked by Wall St. Rank hold IRON as of Q1 2026.

  • Loomis, Sayles & Company held 317,222 shares of Disc Medicine worth $20.3M as of Q1 2026.
  • Loomis, Sayles & Company bought 34,813 Disc Medicine shares in Q1 2026, an estimated $2.42M.
  • Disc Medicine made up 0.03% of Loomis, Sayles & Company's portfolio in Q1 2026, its #237 holding.
  • Loomis, Sayles & Company first reported a position in Disc Medicine in Q4 2025 and has held it in 2 quarters since.
  • Loomis, Sayles & Company's Disc Medicine position peaked at $22.4M in Q4 2025.
  • 203 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.